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Abstract 5HT6 receptor antagonists offer the potential for
safe and effective drugs against obesity, because they can re-
duce weight without causing serious side effects in the cardio-
vascular system. Also, their anorexic effect is associated with
reduced food intake via an enhancement of satiety. In the
present study we investigated the anorexic effect of
idalopirdine (LuAE58054) in a model of obesity induced by
high-fat diet. To induce obesity in rats, the animals were treat-
ed with feed with a fat content of 40 %. Body weight was
controlled and the amount of food and water consumed was
determined. The influence of the test compound on the lipid
profile and glucose level was measured, as well as locomotor
activity in home cages on the 20th day of the treatment.
LuAE58054, at 5 mg kg−1/day i.p., was significantly anorectic
in this model of obesity. Animals treated with LuAE58054
weighed 8 and 9.2 % less than the control obese animals on
the 12th and 21st days, respectively. It significantly reduced
food intake and the amount of peritoneal fat in animals, and
reduced the level of triglycerides in plasma. LuAE58054 did
not have a statistically significant effect on the spontaneous
activity of diet-induced obese rats. The present study clearly
demonstrates the effectiveness of LuAE58054 in reducing
body weight. This compound is in phase III of clinical trials
for the treatment of cognitive deficits associated with
Alzheimer’s disease and schizophrenia. It is a 5HT6 receptor
antagonist and is, therefore, free of those unacceptable side
effects that preclude chronic use of anti-obesity drugs with
other mechanisms of action. The search for an effective and
safe anti-obesity drug is essential for an increasingly obese
population; therefore, the anorectic action of LuAE58054 is
important and there is a need for more research in this
direction.
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Introduction
Obesity is a serious problem in many countries. The World
Health Organization estimates that it affects between 30 and
80 % of adults and up to 30 % of children, and effective
treatment of this disease is one of the major health problems
of the 21st century. The World Health Organization has rec-
ognized obesity as an epidemic of the 21st century (Zięba
2007).
5-Hydroxytryptamine-6 (5-HT6) receptor is a promising
molecular target. There is an impressive increase in the num-
ber of publications and patents in the 5-HT6 receptor field,
demonstrating the high level of interest in research in this area
over recent years (Jastrzębska-Więsek et al. 2013; Heal et al.
2008). Since it has been discovered that 5-HT6 receptor
knock-out mice are resistant to high-fat diet-induced obesity
and since a decrease in food intake and body weight in 5-HT6
receptor knock-out mice has been observed (Caldirola 2003;
Frassetto et al. 2008), researchers have begun to investigate
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the 5HT6 receptor ligands for compounds acting against
obesity.
Acute administration of serotonergic compounds alters the
expression of peptidergic appetitive effectors within the hypo-
thalamus, namely it causes an increase in anorectic pro-
opiomelanocortin mRNA and a decrease in orexigenic neuro-
peptide Y mRNA (Choi et al. 2006). GABAergic neurons
have an inhibitory effect on the act ivity of pro-
opiomelanocortin neurons in the arcuate nucleus, which in-
duces a hunger signal in the hypothalamus. It is believed that
5-HT6 receptor antagonists block the serotonin-dependent ac-
tivation of GABA neurons, which results in reduction of in-
hibitory effects of GABA on pro-opiomelanocortin neurons in
the arcuate nucleus with subsequent inhibition of the hunger
signal induction (Sargent and Henderson 2011).
Various studies have demonstrated the influence of
5HT6 receptor ligands on body weight; it has been
found that the anorexic effect of these compounds is
associated with reduced food intake resulting from a
mechanism that is consistent with an enhancement of
satiety. On the other hand, the 5HT6 receptor ligands
do not cause such clinically unacceptable effects as se-
dation, an emetic reflex, nausea and/or gastrointestinal
malaise and conditioned taste aversion (Heal et al. 2008;
Fisas et al. 2006). Additionally, the results from various
experiments in animal models of human obesity predict
that the weight-loss evoked by the 5-HT6 receptor li-
gands reduces cardio-metabolic risk profiles and causes
an improvement of obesity-related metabolic diseases
(Heal et al. 2008).
LuAE58054 – idalopirdine is a potent and selective 5-HT6
receptor antagonist (Arnt et al. 2010) under development by
Lundbeck as an augmentation therapy for the treatment of
cognitive deficits associated with Alzheimer’s disease and
schizophrenia. Since February 2010 it has been in phase III
clinical trials. LuAE58054 displays high affinity to the human
5-HT6 receptor with a Ki of 0.83 nm. In a 5-HT6 GTPgammaS
efficacy assay, LuAE58054 showed no agonist activity, but
demonstrated potent inhibition of 5-HT-mediated activation.
Besides medium affinity to alpha1A- and alpha1B-
adrenoreceptors, LuAE58054 demonstrated >50-fold selec-
tivity for more than 70 targets examined (Arnt et al. 2010).
Idalopirdine has previously been shown to be safe and well
tolerated in doses of up to 360 mg (single dose) in clinical
pharmacology studies (Wilkinson et al. 2014).
This study is the first to demonstrate, within the model of
obesity, that during the treatment with LuAE58054 animals
significantly lose weight, reaching the weight of animals with-
out obesity, while being at the same time fed normal feed.
Animals treated with LuAE58054 ate significantly less food
when compared to the obese control animals. Reduced fat in
the peritoneum and plasma triglycerides were also observed in
this group of animals.
Materials and methods
Animals
The experiments were carried out on male Wistar rats; initial
bodyweight was 140–160 g (24 animals in total). The animals
were housed in pairs in plastic cages in constant temperature
facilities exposed to 12–12 light–dark cycle. Water and food
were available ad libitum. Control and experimental groups
consisted of six to eight animals each. All experiments were
conducted according to the guidelines of the Animal Use and
Care Committee of the Jagiellonian University (2013,
Poland).
Experimental design
High-fat diet-induced obesity (DIO rats) and its influence
on body weight, food and water intake
Sixteen male Wistar rats (150–160 g) were pair-housed and
fed a fatty diet consisting of 40 % fat blend (Labofeed B with
40 % lard, Morawski, Manufacturer Feed, Poland) for
10 weeks with water available ad libitum. Control rats were
fed a standard diet (Labofeed B, Morawski Manufacturer
Feed, Poland) for 10 weeks. DIO-rats were randomly divided
into two equal groups that had the same mean body weight
and were treated intraperitoneally with a test compound (Lu
AE58054) at 5 mg kg−1/day or a vehicle (5 % HP-beta-cyclo-
dextrin) once per day in the morning between 9.00 and 10.00
for 21 days (Lu group or DIO-control group). Continually to
the last day of the experiment, these animals consumed feed
with 40 % fat. Intakes of food and water were measured three
times per week, and body weight was measured daily, imme-
diately prior to administration of drugs. On the twenty-first
day, the food was discontinued and, in accordance with the
standards, after a twenty-four hour period of fasting blood was
collected for biochemical tests. On the 22st day, 20 min after
intraperitoneal administration of heparin – 1000 units – to rats
anesthetized with thiopental (70 mg kg−1 bw), blood was col-
lected from the left common carotid artery. Plasma was ob-
tained by centrifugation (4000 g/10 min) and then frozen at
−80 °C. Peritoneal fat was collected from the rats and
weighed.
Determination of lipid profiles and glucose levels
in plasma
To determine the lipid profile and glucose level in the plasma,
standard enzymatic, spectrophotometric tests (Biomaxima
S.A. Lublin, Poland) were used. The substrate was
decomposed with appropriate enzymes for the relevant prod-
uct, which was converted to a colored compound. Coloration
was proportional to their concentration. The absorbance was
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measured at a wavelength of 500 (glucose, triglycerides, total
cholesterol) or 600 nm (HDL, LDL).
Locomotor activity test
The locomotor activity of rats was measured on the 20th day
of the treatment with a special RFID-system – TraffiCage
(TSE-Systems, Germany). The rats were housed in pairs in
home cages with feed and water available ad libitum. The
animals were subcutaneously implanted with transmitter iden-
tification (RFID), which enabled the presence and time spent
in different areas of the cage to be counted and then the data
was grouped in a special computer program.
Data analysis and statistical procedures
Statistical calculations were carried out with the GraphPad
Prism 6 program. The results were given as the arithmetic
means with standard error of the mean (SEM). The statistical
significance was calculated using the one-way ANOVA post-
hoc Tukey Multiple Comparison Test or the two-way
ANOVA post-hoc Bonferroni Multiple Comparison Test or
the t-Student Test (for comparison two groups). Differences
were considered statistically significant at: *p≤0.05, **p≤
0.01, ***p≤0.001.
Drugs, chemical reagents and other materials
Heparin was delivered by Polfa Warszawa S.A. (Warsaw,
Poland), while thiopental sodium was from Sandoz
International (Stryków, Poland) and 5 % HP-beta-
cyclodextrin from Sigma-Aldrich, USA.
Lu AE58054 was synthesized in the Chair of
Pharmaceutical Chemistry, Faculty of Pharmacy,
Jagiellonian University Medical College, Kraków, Poland ac-
cording to a procedure described previously (Pasternak and
Szymonifka 2009). The structure was confirmed by HNMR
obtained in a Varian BB 200 spectrometer using TMS
(0.00 ppm) in chloroform-d1. The purity was confirmed by
UPLC/MS analysis to be>98 %. The UPLC/MS system
consisted of a Waters AQUITY UPLC® coupled to a Waters
SQD mass spectrometer. Chromatographic separations were
carried out using an Acquity UPLC® BEH C18 column, 2.1×
100mm and 1.7 μm particle size. The columnwas maintained
at 60 °C, and eluted under gradient conditions: 4 min, a linear
gradient from 80 to 0.1 % of eluent A at a flow rate of 0.5 ml/
min. Eluent A: water/formic acid (0.02 %, v/v) and eluent B:
methanol – acidic gradient. Eluent A: water/formic
acid/ammonia solution (0.01 %/0.1 %, v/v/v) and Eluent B:
methanol – alkaline gradient.
Results
Reduction of weight after LuAE58054 administration
to DIO rats
LuAE58054 administered intraperitoneally to rats fed on
a high-fat feed caused a significant decrease in body
weight gain compared to the obese rats (DIO-control
group). It significantly reduced body weight to the level
of the non-obese rats (control group - standard diet-fed
rats) on the 12th day of treatment. Animals treated with
LuAE58054 weighed 8 and 9.2 % less than the control
obese animals on the 12th and 21st days, respectively.
LuAE58054 did not influence body weight in rats fed a
standard feed. The results are shown in Fig. 1.
Influence of the test compound on the amount
of peritoneal adipose tissue
In the group receiving the test compound – LuAE58054 – the
amount of fat in peritonea was significantly lower than in
obese rats. Furthermore, the mass of adipose tissue was also
significantly lower than in rats of the control, non-obese
group, with a comparable weight of the whole body. The
results are shown in Fig. 2.
Influence of LuAE58054 on food and water intake
There was a reduction of food intake in the group treated with
LuAE58054 in comparison with the DIO-control group.
Statistical significance was determined in the second week.
In this period, weight loss was observed in treatment animals.
The results are shown in Fig. 3a. In the first week of treatment
with LuAE58054, a significant increase in water intake was
observed in comparison with the intake in the DIO-control
group, whereas in the next weeks of treatment a significant
decrease in water consumption in rats treated with
LuAE58054 was determined. The results are shown in
Fig. 3b.
Influence of chronic 21-day treatment with LuAE58054
on lipid and carbohydrate profiles in rats fed a high-fat
diet
Treatment with Lu AE58054 for 21 days significantly
decreased the level of triglycerides in plasma in rats
fed with high-fat feed. This compound did not influ-
ence the blood glucose, total cholesterol and HDL cho-
lesterol fraction or LDL. The results are shown in
Table 1.
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Locomotor Activity after 20 days of treatment with Lu
AE58054
In the group treated with the tested compound – Lu AE58054
– no statistically significant effect on the spontaneous activity
of DIO rats was observed in comparison with the DIO-control
group. Figure 4 shows the results.
Discussion
Obesity leads to disruption of the functioning of the human
body and an increase in the prevalence of various chronic
diseases and mortality (Zięba 2007). Obese individuals are
more likely to suffer from cardiovascular diseases (ischemic
heart disease, hypertension, diabetes, and diseases of the
digestive system) and they are at higher risk of developing
colorectal, gallbladder, pancreas and kidney cancers.
Treatment of obesity is very difficult and expensive.
Development of additional diseases due to obesity also gener-
ates huge costs of treatment (World Obesity Federation 2014).
Therefore, the search for compounds that effectively help re-
duce weight and show low risk for potential side effects is
extremely important for the general public.
Oral administration to rats of LuAE58054 potently
inhibited striatal in-vivo binding of the 5-HT6 antagonist
radioligand [3H]LuAE60157, with an ED50 of 2.7 mg/kg.
Steady-state modeling of an acute pharmacokinetic/5-HT6 re-
ceptor occupancy time-course experiment indicated a plasma
EC50 value of 20 ng/ml. Administration of LuAE58054 in a
dose range (5–20 mg/kg p.o.) led to more than 65 % striatal 5-
HT6 receptor binding occupancy in vivo. These results
Fig 1 Effect of chronic administration of the 5-HT6 receptor antagonist,
LuAE58054, on body weight in dietary-induced obese male Wistar rats.
Results are means ± SEM, n=6–8. Multiple comparisons of the vehicle-
treated control group against the vehicle-treated DIO-control group (*) or
LuAE58054-treated group against the vehicle-treated DIO-control group
(#) or LuAE58054-treated group against the vehicle-treated control group
(^) were by two-way ANOVA, post-hoc Benferroni test. Significant dif-
ferences are denoted by *, #, ^ p<0.05, **, ## p<0.01
Fig 2 Weight of peritoneal fat
after chronic administration of the
5-HT6 receptor antagonist –
LuAE58054 – to male Wistar rats
(control non-obese, control DIO
obese, Lu – obese treated with
LuAE58054). Results are means
± SEM, n=6–8. Comparisons
against the vehicle-treated control
group (*) or against the DIO-
control group (#) were by one-
way ANOVA, post-hoc Tukey
test. Significant differences are
denoted by ** p<0.01, ###
p<0.001
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indicate that LuAE58054 is a selective antagonist of 5-HT6
(Arnt et al. 2010).
Research into the influence of LuAE58054 (idalopirdine)
on body weight in animals with diet-induced obesity was per-
formed by intraperitoneal injection of 5 mg kg−1 bw of the
compound for 21 days. This dose was the lowest effective
dose in a rat model of cognitive impairment (Arnt et al.
2010). Intraperitoneal injection was chosen as an administra-
tion route to ensure that the high-fat diet did not influence the
compound absorption. This route of administration has also
been used in research into the influence on body weight of
another 5-HT6 receptor antagonist - PRX-07034 - in a similar
model of high-fat diet-induced obesity (Heal et al. 2008).
Fig 3 Effect of chronic
administration of the 5-HT6
receptor antagonist, LuAE58054,
on food intake (a) or water intake
(b) in dietary-induced obese male
Wistar rats. Results are means ±
SEM, data for two animals reared
together, n=3–4. Multiple
comparisons against the DIO-
control group were by two-way
ANOVA, post-hoc Bonferroni
test. Significant differences are
denoted by *p<0.05, **p<0.01,
***p<0.001
Table 1 Effects of chronic administration of the 5-HT6 receptor
antagonist, LuAE58054, on glucose, triglycerides, total cholesterol,
HDL cholesterol or LDL cholesterol levels in plasma control and
dietary-induced obese male Wistar rats
Glucose TG Cholesterol HDL LDL
Control 4.61 0.18 1.61 0.79 0.97
Control-DIO 5.70## 0.23# 3.62## 1.73## 1.83##
Idalopirdine 6.11## 0.17** 3.45## 1.77## 1.89##
Results are means ± SEM, n=6–8. Concentrations in plasma: mmol/l.
Comparisons against the DIO-control group were by t-Student test. Sig-
nificant differences are denoted by **p<0.01. Comparisons against the
control group were by t-Student test. Significant differences are denoted
by #p<0.05 or ##p<0.01
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In safety and efficacy studies with idalopirdine in patients
with moderate Alzheimer’s disease, this compound reduced
body weight only in 5 % of patients, and this effect was not
significant (Wilkinson et al. 2014). However, there was a no-
table difference between the elderly people who were the fo-
cus of the research and a population of obese people. Changes
in body weight can affect the overall health of elderly patients
and should not occur in these individuals. In particular, weight
loss can lead to many health complications affecting daily
activities, loss of functional status and mortality. Even looking
for drugs that increase body weight in these people (Hilas and
Avena-Woods 2014).
Our research has been conducted on the model of obesity.
The research clearly showed a significant reduction of body
fat and triglycerides in animals which were disrupted in these
parameters – obesity model. This is the first report showing
that idalopirdine has therapeutic potential against obesity.
Obesity is a major cause of insulin resistance, impaired
glucose tolerance, type II diabetes, elevated plasma concen-
trations of triglycerides and low density cholesterol and de-
creased plasma concentrations of high density cholesterol and
hypertension (Mokdad et al. 2001; Pi-Sunyer 2002). It is im-
portant, therefore, that in animals treated with LuAE58054 an
anorectic effect occurred in parallel with lower plasma triglyc-
eride levels compared to those in the obese control animals.
After 21 days of treatment with Lu AE58054 the fat pads in
peritoneal tissues of the rats were weighed and decreases in
visceral fat depots were observed. Idalopirdine also caused a
Fig 4 Locomotor Activity during
24 h after treatment with
LuAE58054 or vehicle to DIO
rats on 20th day of treatment.
Activity is directly related to
entering various areas of the cage
(a) and inversely related to time
spent in particular areas of the
cage (b). Results are means, n=6
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statistically significant reduction in visceral fat depots in rats
without induced obesity. This is interesting, because there was
no weight loss in rats fed standard feed treated with
idalopirdine. Additional studies are, therefore, needed to de-
termine why this occurred and what its cause was.
The present studies indicated that the reduction in food
intake in obese animals during administration of
LuAE58054 is associated with a reduction in their weight.
This is consistent with the observations of many researchers
who assert that the anorexic effect of 5-HT6 ligands is associ-
ated with reduced food intake via a mechanism that is consis-
tent with an enhancement of satiety (Heal et al. 2008).
Administration of Lu resulted in statistically significant
changes in water intake in different weeks of treatment. In the
first week, a statistically significant increase in water consump-
tion was observed compared to the intake of the control group.
It is assumed that increased intake of water can reduce food
intake (Muckelbauer et al. 2013). Those rats fed a high fat meal
take less water than rats fed a standard feed (data not shown),
which may be related to the fact that a high-fat feed in the form
of a paste is not as dry as the standard feed. To understand why
it is that in the second and third week a decline in the uptake of
water is observed, it is necessary to look for the cause. In the
literature there are no reports focusing on the effect of 5-HT6
ligands on water consumption, apart from the impact on water
intake in a free-drinking test, where the SB-258585 – antagonist
of these receptors did not affect the intake of water after a single
administration (Wesołowska et al. 2007). It is known that the
stimulation of 5HT1A or 5-HT1B receptors leads to a decrease in
water consumption (Clissold et al. 2013). Increasing the water
intake by animals can be associated with activation of metabol-
ic processes, such as increases in both fatty acid oxidation and
energy expenditure (Jbilo et al. 2005; Liu et al. 2005). The
increase in drinking may be related to an increase in thermo-
genesis, as in studies with sibutramine administration in ani-
mals (Connoley et al. 1999; Skill et al. 2000). In the literature,
there are other studies where sibutramina does not affect the
level of water intake in rat models of diet-induced obesity (Pratt
and Connolly 2010). Further detailed studies are needed to
confirm the effect of idalopirdine and other serotonin receptor
ligands on water consumption, and to ascertain whether this is
linked with the effect of decreasing body weight.
Disorders of spontaneous activity (significant increase in ac-
tivity as well as sedation) and the stress induced by the test com-
pound could be very disadvantageous and could disturb an im-
pact assessment of the test compound on bodyweight. This study
demonstrated that repeated administration of Lu AE58054 to
obese rats did not induce stress. It was essential to house animals
in pairs in home cages. The test compound does not cause seda-
tion. Therefore, the observed anorectic effect was definitely not
associatedwith a reduction in the spontaneous activity of animals.
The anorectic effect of LuAE58054 in the model of obesity
where the animals were treated with high-fat feed ad libitum
(DIO) was comparable to the anorectic effects of other 5-HT6
receptor ligands. In this model of obesity, 5 weeks of intraper-
itoneal treatment with PRX-07034 at the dose of 10 mg kg−1
bw/day caused a moderate decrease in rats’ food consumption
and weight-loss (Heal et al. 2008). BVT 5182 – the other
antagonist of the 5-HT6 receptor – was also shown to produce
a reduction in food intake and body weight in DIO rats, si-
multaneous with decreases in visceral adiposity. This com-
pound has presented anorectic activity in DIO mice and ob/
ob mice too, when administered subcutaneously at a dose of
3 mg kg−1 bw (Heal et al. 2008). Ro 04–6790 at a high dose of
30 mg kg−1 i.p. also significantly attenuates body weight-gain
in growing rats when given daily for 3 days (Woolley et al.
2001). E6837 – a partial agonist of the 5-HT6 receptor - when
administered intragastrically at a dose of 30 mg kg−1 bw twice
a day for 30 days reduces weight and food intake (Fisas et al.
2006). A comparison of the anorectic effects of Lu AE58054
and the mentioned ligands is presented in Table 2.
The anorexic effect of Lu AE58054 shown in this study was
also comparable to that of sibutraminewhich, when administered
intragastrically for 21 days at a dose of 3 mg kg−1 bw/day to
high-fat-fed obese rats, reduced their body weight by 10 %
(Brown et al. 2001); while when administered at a dose of 5
mg kg−1 bw day for 28 days resulted in weight loss of 10.8 %
(Fisas et al. 2006), and at a dose of 7.5 mg kg−1 bw/day for
28 days reduced body weight by 7.6 % (Hansen et al. 2010).
The proportion of patients achieving weight loss of at least
5 % ranges from 37 to 47 % for lorcaserin, 35 to 73 % for
orlistat, and 67 to 70 % for top-dose phentermine plus
topiramate–extended release. The safety and efficacy of these
drugs have been determined for short-term use and there is
Table 2 Anorectic effect after chronic administration of certain compounds to DIO rats





















10.70 % 15.60 % 10 % 10.80 % 7.60 % 9.20 %
Percentage difference in comparison to DIO group at the end of treatment: A (Heal et al. 2008), B (Fisas et al. 2006), C (Brown et al. 2001), D. (Fisas
et al. 2006), E. (Hansen et al. 2010), F. this study
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limited data for their long-term use (Yanovski and Yanovski
2014). These data emphasize the need for drugs with different
mechanisms of action, with improved efficacy and greater
safety potential. 5-HT6 receptor antagonists do not cause dis-
turbances in the cardiovascular system (Heal et al. 2008);
therefore, the search for drugs against obesity in this group
of drugs is particularly advantageous and important.
Conclusion
This study is the first to use the model of obesity to demonstrate
that animals lost a significant amount of weight during treatment
with Lu AE58054. In dietary-induced obese rats, LuAE58054
led to significant signs of decreasing weight: reduced food in-
take, the amount of fat deposits in the peritoneum and the level
of plasma triglycerides. Long-term administration did not lead to
animal stress or sedation. The obtained data clearly indicate that
idalopirdine is a compound with anti-obesity potential.
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